November 26, 2018 08:23 AM EST
Pharma

Af­ter falling off a cliff, Edge Ther­a­peu­tics pro­vides can­cer-fo­cused PDS Biotech a re­verse merg­er on­to Nas­daq

ENDPOINTS

Bat­tered by a late-stage set­back in March, tiny Edge Ther­a­peu­tics $EDGE has pro­vid­ed can­cer im­munother­a­py com­pa­ny PDS Biotech­nol­o­gy Corp. a ve­hi­cle for a quick re­verse …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

A service from the Financial Times